| 7.50 Data as of May 17 |  +0.01 / +0.13%Today’s Change | 3.71 Today|||52-Week Range 11.88 | -16.85% Year-to-Date |
| SECTOR Health Technology | INDUSTRY Pharmaceuticals: Other | MARKET CAP $518.5M |
Synta Pharmaceuticals Corp. 45 Hartwell Avenue Lexington Massachusetts 02421 |
| Individual stakeholders | 35.13% |
| Other institutional | 23.19% |
| Mutual fund holders | 17.53% |
| Safi R. Bahcall, PhD | President, Chief Executive Officer & Director |
| Keith S. Ehrlich, MBA, CPA | Chief Financial Officer & VP-Administration |
| Iman El-Hariry, MD, PhD | Vice President-Clinical Research |
| Sumant Ramachandra, MD, PhD | President-Research & Development |
| Vojo Vukovic, MD, PhD | Chief Medical Officer & Senior Vice President |
.
